Skip to main content
Erschienen in: Tumor Biology 10/2014

01.10.2014 | Research Article

Silencing survivin activates autophagy as an alternative survival pathway in HCC cells

verfasst von: Yu-Jia Chang, Li-Tzu Li, Hsin-An Chen, Chin-Sheng Hung, Po-Li Wei

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Autophagy is a survival mechanism that is activated in response to nutrient deprivation. The link between aberrant autophagy and cancer has been increasingly recognized. Survivin, an anti-apoptotic molecule, and the autophagy pathway are correlated with therapeutic responses to cancer. However, the role of autophagy in cancer progression remains unclear. Here, we generated survivin knockdown cells (survivin-KD) by introducing a short interfering RNA (siRNA) into hepatocellular carcinoma (HCC) cells, and we observed a 20 % reduction in the survival of these survivin-KD cells, as determined by MTT assay. In addition, an increased number of stress granules, increased positive staining by acridine orange and a shift in the high side scatter (SSC) cell population in flow cytometry analysis were observed in survivin-KD cells. Furthermore, electron microscopy revealed an increased number of autophagosomes in survivin-KD cells compared with scrambled control cells. Finally, we treated cells with an autophagy inhibitor, 3-MA, and observed a decrease in cell survival in survivin-KD cells compared with scrambled control cells. Our study suggests that an autophagy signal may be activated after the anti-apoptotic molecule survivin is suppressed. This finding implies that autophagy may be an alternative survival pathway in HCC cells and may provide a basis for the development of new therapeutic strategies for HCC.
Literatur
1.
Zurück zum Zitat LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–59.CrossRefPubMed LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–59.CrossRefPubMed
2.
Zurück zum Zitat Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133–9.CrossRefPubMed Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133–9.CrossRefPubMed
3.
Zurück zum Zitat Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41:599–607.CrossRefPubMed Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41:599–607.CrossRefPubMed
4.
Zurück zum Zitat Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59:1406–12.CrossRefPubMed Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59:1406–12.CrossRefPubMed
5.
Zurück zum Zitat Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–7.PubMed Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–7.PubMed
6.
Zurück zum Zitat Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64:293–302.CrossRefPubMed Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64:293–302.CrossRefPubMed
8.
Zurück zum Zitat A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: The cancer of the liver italian program (clip) investigators. Hepatology. 1998;28:751–5. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: The cancer of the liver italian program (clip) investigators. Hepatology. 1998;28:751–5.
9.
Zurück zum Zitat Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials. 2010;31:55–61.CrossRefPubMed Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials. 2010;31:55–61.CrossRefPubMed
10.
Zurück zum Zitat Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993;113:612–8.PubMed Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993;113:612–8.PubMed
11.
Zurück zum Zitat Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver cancer study group of Japan. Ann Surg. 1990;211:277–87. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver cancer study group of Japan. Ann Surg. 1990;211:277–87.
12.
Zurück zum Zitat Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery. 1989;106:740–8. discussion 748–749.PubMed Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery. 1989;106:740–8. discussion 748–749.PubMed
13.
Zurück zum Zitat Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Muting D, Rambach W. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg. 1991;78:459–62.CrossRefPubMed Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Muting D, Rambach W. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg. 1991;78:459–62.CrossRefPubMed
14.
Zurück zum Zitat Hu H, Li Z, Chen J, Wang D, Ma J, Wang W, et al. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating akt/survivin signalling in hepatocellular carcinoma cells. Gut. 2011;60:710–21.CrossRefPubMed Hu H, Li Z, Chen J, Wang D, Ma J, Wang W, et al. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating akt/survivin signalling in hepatocellular carcinoma cells. Gut. 2011;60:710–21.CrossRefPubMed
17.
Zurück zum Zitat Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, et al. Survivin-mediated cancer cell migration through grp78 and epithelial-mesenchymal transition (emt) marker expression in mahlavu cells. Ann Surg Oncol. 2012;19:336–43.CrossRefPubMed Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, et al. Survivin-mediated cancer cell migration through grp78 and epithelial-mesenchymal transition (emt) marker expression in mahlavu cells. Ann Surg Oncol. 2012;19:336–43.CrossRefPubMed
18.
Zurück zum Zitat Hung CS, Lin SF, Liu HH, Kuo LJ, Li LT, Su HY, et al. Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:2744–52.CrossRefPubMed Hung CS, Lin SF, Liu HH, Kuo LJ, Li LT, Su HY, et al. Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:2744–52.CrossRefPubMed
19.
Zurück zum Zitat Hung CS, Liu HH, Huang MT, Cheng CW, Kuo LJ, Ho YS, et al. Knockdown survivin expression reduces the efficacy of curcumin treatment in hepatocellular carcinoma cells. Ann Surg Oncol. 2012;19:3547–55.CrossRefPubMed Hung CS, Liu HH, Huang MT, Cheng CW, Kuo LJ, Ho YS, et al. Knockdown survivin expression reduces the efficacy of curcumin treatment in hepatocellular carcinoma cells. Ann Surg Oncol. 2012;19:3547–55.CrossRefPubMed
20.
Zurück zum Zitat Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.CrossRefPubMed Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.CrossRefPubMed
21.
Zurück zum Zitat Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on hiv-1: interaction of oligomannose dendrons with human monoclonal antibody 2g12 and dc-sign. Proc Natl Acad Sci U S A. 2008;105:3690–5.CrossRefPubMedPubMedCentral Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on hiv-1: interaction of oligomannose dendrons with human monoclonal antibody 2g12 and dc-sign. Proc Natl Acad Sci U S A. 2008;105:3690–5.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect t cells over long distances presenting a novel route for hiv-1 transmission. Nat Cell Biol. 2008;10:211–9.CrossRefPubMed Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect t cells over long distances presenting a novel route for hiv-1 transmission. Nat Cell Biol. 2008;10:211–9.CrossRefPubMed
23.
Zurück zum Zitat Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (grp78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.CrossRefPubMed Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (grp78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.CrossRefPubMed
24.
Zurück zum Zitat Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy. 2010;6:353–65.CrossRefPubMed Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy. 2010;6:353–65.CrossRefPubMed
25.
Zurück zum Zitat Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103–8.PubMed Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103–8.PubMed
26.
Zurück zum Zitat Traganos F, Darzynkiewicz Z. Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol. 1994;41:185–94.CrossRefPubMed Traganos F, Darzynkiewicz Z. Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol. 1994;41:185–94.CrossRefPubMed
28.
Zurück zum Zitat Han L, Tang C, Yin C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials. 2014;35:4589–600.CrossRefPubMed Han L, Tang C, Yin C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials. 2014;35:4589–600.CrossRefPubMed
29.
Zurück zum Zitat Necochea-Campion R, Chen CS, Mirshahidi S, Howard FD, Wall NR. Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett. 2013;339:167–74.CrossRefPubMedPubMedCentral Necochea-Campion R, Chen CS, Mirshahidi S, Howard FD, Wall NR. Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett. 2013;339:167–74.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Wang Q, Chen Z, Diao X, Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant ym155 in prostate cancer cells. Cancer Lett. 2011;302:29–36.CrossRefPubMed Wang Q, Chen Z, Diao X, Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant ym155 in prostate cancer cells. Cancer Lett. 2011;302:29–36.CrossRefPubMed
31.
Zurück zum Zitat Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol. 2009;34:729–42.PubMedPubMedCentral Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol. 2009;34:729–42.PubMedPubMedCentral
33.
Zurück zum Zitat Niu TK, Cheng Y, Ren X, Yang JM. Interaction of beclin 1 with survivin regulates sensitivity of human glioma cells to trail-induced apoptosis. FEBS Lett. 2010;584:3519–24.CrossRefPubMedPubMedCentral Niu TK, Cheng Y, Ren X, Yang JM. Interaction of beclin 1 with survivin regulates sensitivity of human glioma cells to trail-induced apoptosis. FEBS Lett. 2010;584:3519–24.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Hou MF, Kuo HC, Li JH, Wang YS, Chang CC, Chen KC, et al. Orai1/cracm1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in a549 lung cancer cells. Biochim Biophys Acta. 1810;2011:1278–84. Hou MF, Kuo HC, Li JH, Wang YS, Chang CC, Chen KC, et al. Orai1/cracm1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in a549 lung cancer cells. Biochim Biophys Acta. 1810;2011:1278–84.
35.
Zurück zum Zitat Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, et al. Involvement of store-operated calcium signaling in EGF-mediated cox-2 gene activation in cancer cells. Cell Signal. 2012;24:162–9.CrossRefPubMed Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, et al. Involvement of store-operated calcium signaling in EGF-mediated cox-2 gene activation in cancer cells. Cell Signal. 2012;24:162–9.CrossRefPubMed
36.
Zurück zum Zitat Chang WC, Woon PY, Hsu YW, Yang S, Chiu YC, Hou MF. The association between single-nucleotide polymorphisms of orai1 gene and breast cancer in a Taiwanese population. Sci World J. 2012;2012:916587. Chang WC, Woon PY, Hsu YW, Yang S, Chiu YC, Hou MF. The association between single-nucleotide polymorphisms of orai1 gene and breast cancer in a Taiwanese population. Sci World J. 2012;2012:916587.
37.
Zurück zum Zitat Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34.CrossRefPubMed Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34.CrossRefPubMed
38.
Zurück zum Zitat Huang WC, Chai CY, Chen WC, Hou MF, Wang YS, Chiu YC, et al. Histamine regulates cyclooxygenase 2 gene activation through orai1-mediated NFkappaB activation in lung cancer cells. Cell Calcium. 2011;50:27–35.CrossRefPubMed Huang WC, Chai CY, Chen WC, Hou MF, Wang YS, Chiu YC, et al. Histamine regulates cyclooxygenase 2 gene activation through orai1-mediated NFkappaB activation in lung cancer cells. Cell Calcium. 2011;50:27–35.CrossRefPubMed
Metadaten
Titel
Silencing survivin activates autophagy as an alternative survival pathway in HCC cells
verfasst von
Yu-Jia Chang
Li-Tzu Li
Hsin-An Chen
Chin-Sheng Hung
Po-Li Wei
Publikationsdatum
01.10.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2257-6

Weitere Artikel der Ausgabe 10/2014

Tumor Biology 10/2014 Zur Ausgabe

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.